Welcome to our dedicated page for SHUTTLE PHARMACTCLS HLDGS news (Ticker: SHPH), a resource for investors and traders seeking the latest updates and insights on SHUTTLE PHARMACTCLS HLDGS stock.
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) generates news at the intersection of oncology drug development and artificial intelligence–driven molecular discovery. Public updates highlight the company’s efforts to improve outcomes for cancer patients treated with radiation therapy, as well as its ownership and deployment of the Molecule.ai platform, a pharmaceutical software AI-driven system for molecular discovery and early-stage drug development.
Recent news releases describe several key themes. Shuttle Pharma has reported on its historical Phase II clinical trial of Ropidoxuridine (IPdR) in glioblastoma patients undergoing radiation therapy, including enrollment progress and tolerability data, and later on its decision to discontinue those clinical trials and initiate winddown activities in coordination with its contract research organization and clinical sites. These items provide context on the evolution of the company’s oncology pipeline and its strategic reassessment of clinical programs.
Another major news focus is the acquisition and integration of Molecule.ai. Press releases and 8-K filings detail a binding term sheet, asset purchase agreement and closing of the transaction under which a Shuttle Pharma subsidiary acquired substantially all of the assets and liabilities of the Canadian AI company operating Molecule.ai. Coverage explains how the platform supports molecular property prediction, drug-target interaction modeling, cross-property evaluation and structured reasoning, and how Shuttle Pharma aims to use these capabilities to augment its drug discovery and development activities.
News items also address capital markets and regulatory developments, such as a private placement involving a pre-funded warrant, related S-1 and S-1/A registration statements for resale of the underlying shares, and communications regarding Nasdaq listing requirements and a reverse stock split undertaken as part of a compliance initiative. Together, these disclosures offer investors and observers a view into SHPH’s scientific programs, AI platform strategy, financing transactions and listing status.
For readers following SHPH news, the company’s updates provide ongoing insight into its transition from a radiation-sensitizer–focused clinical-stage pharmaceutical profile toward a combined biotechnology and AI-driven molecular discovery business model.
Shuttle Pharmaceuticals (NASDAQ: SHPH) on January 13, 2026 highlighted Utah's new pilot allowing AI to authorize prescription refills and explained why that regulatory milestone matters for its Molecule.ai drug‑discovery platform. The release links Utah's AI refill program to time and cost savings in healthcare and argues Molecule.ai can similarly cut drug discovery bottlenecks by reducing time to identify candidates, lowering failed‑experiment costs, and automating repetitive screening.
The company says Molecule.ai uses agentic AI with uncertainty quantification, human‑in‑the‑loop workflows, and explainable models to enable oversight and scale while aiming to accelerate R&D and improve access to therapies.
Shuttle Pharmaceuticals (NASDAQ: SHPH) announced it closed the acquisition of substantially all assets and liabilities of 1542770 B.C. Ltd. d/b/a Molecule.ai for a total purchase price of $8 million payable in cash and Shuttle common stock, plus a contingent $2 million in cash and stock tied to performance milestones.
An initial $3 million was paid at closing; remaining consideration will be delivered over time and, for contingent payments, subject to milestone achievement and Molecule's election of cash or equity. Shuttle said the acquisition adds an AI molecular modeling and predictive analytics platform to its drug discovery and development capabilities.
Shuttle Pharmaceuticals (NASDAQ: SHPH) entered a securities purchase agreement with a single investor to raise approximately $2.5 million in gross proceeds via the sale of a pre-funded warrant that can be exercised into up to 625,156 shares at an effective price of $4.00 per share. The price is described as above-the-market under Nasdaq rules. The Offering is expected to close on or about November 4, 2025, subject to customary closing conditions.
WestPark Capital is the exclusive placement agent. The company intends to use net proceeds for marketing, general corporate purposes and working capital and has agreed to file registration statement(s) to cover resale of shares issuable upon exercise of the pre-funded warrant.
Shuttle Pharmaceuticals (NASDAQ:SHPH) announced a definitive Letter of Intent dated October 22, 2025 to acquire substantially all assets and liabilities of Molecule.ai for approximately $10 million, payable in a mix of cash and common stock with timing and ratios tied to performance milestones. Molecule.ai provides an AI platform designed to reason with scientific data, predict molecular interactions, and iterate designs in real time. Shuttle positions the deal as a strategic shift from a chemistry-focused biotech to a hybrid platform company aiming to scale discovery through perpetual machine learning.
Shuttle Pharmaceuticals (NASDAQ:SHPH) signed a definitive letter of intent on October 22, 2025 to acquire substantially all assets and liabilities of Molecule.ai for $10 million, payable in cash and Shuttle common stock with milestone‑contingent timing and mix. Molecule.ai provides an Agentic AI Mode that automates drug discovery workflows, including drug‑target interaction simulation and molecular property reasoning, which Shuttle says can shorten early R&D timelines by months. Shuttle plans to integrate the platform with its oncology programs to accelerate discovery of radiation sensitizers and create a self‑learning discovery engine with potential cross‑therapeutic licensing options.
Shuttle Pharmaceuticals (NASDAQ:SHPH) announced a definitive Letter of Intent dated October 21, 2025 to acquire substantially all assets of 1542770 BC Ltd. (Molecule) for approximately US $10 million in cash and stock, aiming to integrate Molecule.ai's predictive platform with Shuttle's lead radiotherapy sensitizer Ropidoxuridine (IPdR). The release reports Phase 2 glioblastoma progress (nearly half randomized; 84% completed all treatment cycles) and Orphan Drug designation for IPdR. The content discloses the author was paid USD $10,000 for sponsored coverage and contains forward-looking statements subject to closing and regulatory risks.
Shuttle Pharmaceuticals (NASDAQ: SHPH) announced a binding term sheet to acquire substantially all assets and liabilities of 1542770 BC Ltd. ("Molecule"), a Canadian AI molecular discovery company, for a $10 million total purchase price payable in cash and Shuttle common stock.
The final cash/equity mix will be determined by Shuttle and payments are subject to performance milestones. Closing requires mutual due diligence and execution of definitive agreements with customary conditions.
The company said the acquisition aims to expand Shuttle's AI molecular modeling and predictive analytics capabilities to support its precision radiotherapy drug-discovery pipeline.
Shuttle Pharmaceuticals (Nasdaq: SHPH) executed a non-binding letter of intent to acquire Molecule.ai, an AI drug-discovery platform founded by Dr. ZT Zhang, on October 10, 2025. The LOI contemplates Shuttle acquiring all rights to Molecule.ai and assuming its liabilities, with Molecule.ai extending its platform to support Drug-Target Interaction modeling and delivering a first version of an Agentic AI mode.
Consideration is a $10 million purchase price payable at closing in a mix of cash and Shuttle common shares and subject to milestone completion; specific milestone terms are to be determined by both parties.
Shuttle Pharmaceuticals (Nasdaq: SHPH) announced a non-binding letter of intent dated Oct 9, 2025 to acquire AI developer Molecule.ai for a $10 million purchase price payable at closing subject to milestones.
Molecule.ai provides an AI drug-discovery platform using LLMs with modules for molecule property prediction, drug-target interaction modeling, and an initial Agentic AI mode to automate multi-step discovery workflows. Shuttle will acquire all rights and assume liabilities; Molecule.ai will extend the platform and assist hiring. Consideration will be a mix of cash and Shuttle common shares tied to milestone completion.
Shuttle Pharmaceuticals (Nasdaq: SHPH), a specialty pharmaceutical company focused on improving radiation therapy outcomes, provided a Q2 2025 corporate update highlighting significant progress in its clinical trials. The company's Phase 2 trial of Ropidoxuridine for glioblastoma treatment has reached 63% enrollment, with 72% of enrolled patients completing all seven cycles and reporting good tolerability.
Key financial developments include securing $4.25 million through a private placement, ending Q2 with $4.8 million in cash. The company completed a reverse stock split for Nasdaq compliance and strengthened its leadership by appointing George Scorsis as Board Chairman and Christopher Cooper to the Board. The Phase 2 trial completion is expected in late 2025, with data readouts anticipated in 2026.
FAQ
What is the current stock price of SHUTTLE PHARMACTCLS HLDGS (SHPH)?
What is the market cap of SHUTTLE PHARMACTCLS HLDGS (SHPH)?
